Yet another biotech stock that is so far refusing to go down amid a major market decline today is Warner Chilcott (WCRX), a specialty pharmaceutical company focused on the women's health care, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The short-sellers have done a number on this stock so far in 2011, with shares off by over 29%.
This company received some favorable legal news today, after a district court granted a preliminary injunction that prevents Mylan (MYL) from launching a generic version of its oral antibiotic. This bullish development had at one point today sent the stock up by over 5.5%.
If you look at the chart for Warner Chilcott, you'll see that this stock has been beaten down big in the last few months, dropping from its July high of $24.65 to a recent low of $13.63 a share. The stock is also now trading below both its 50-day and 200-day moving averages, which is bearish. That said, the stock is approaching a major breakout above a key descending trend line that started back in early August. This descending trend line has acted as stiff resistance for two months now, so a move above it should be considered bullish.At last check, this stock has given back a big chunk of its initial run today to $16.49 a share and is now trading at around $15 a share. This puts the relative strength theory in question until we see how the stock closes today. If it closes up, then I would consider that a bullish development. I wouldn't be a buyer of this stock unless you see it break out above that key descending trend line, which will trigger at around $16.60 a share. If we get that move, then add to any long position once the stock takes out its 50-day moving average of $18.04 a share on big volume. Look for volume that's tracking in close to or above its three-month average action of 2.3 million shares.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV